{"id":"https://openalex.org/W3096654615","doi":"https://doi.org/10.1182/blood-2020-141720","title":"Hepcidin Peptidomimetics - Oral Efficacy in Pre-Clinical Disease Model of Iron Overload","display_name":"Hepcidin Peptidomimetics - Oral Efficacy in Pre-Clinical Disease Model of Iron Overload","publication_year":2020,"publication_date":"2020-11-04","ids":{"openalex":"https://openalex.org/W3096654615","doi":"https://doi.org/10.1182/blood-2020-141720","mag":"3096654615"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2020-141720","doi":"https://doi.org/10.1182/blood-2020-141720","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-141720","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5060145046","display_name":"Roopa Taranath","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091875","display_name":"Protagonist Therapeutics (United States)","ror":"https://ror.org/00bp7kt89","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091875"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Roopa Taranath","raw_affiliation_strings":["Protagonist Therapeutics, Newark, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Protagonist Therapeutics, Newark, CA","institution_ids":["https://openalex.org/I4210091875"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063464436","display_name":"Gregory T. Bourne","orcid":"https://orcid.org/0000-0002-2792-2895","observed_orcids":["https://orcid.org/0000-0002-2792-2895"]},"institutions":[{"id":"https://openalex.org/I4387156166","display_name":"Protagonist Therapeutics (Australia)","ror":"https://ror.org/031xcxv56","country_code":"AU","type":"company","lineage":["https://openalex.org/I4387156166"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Gregory Bourne","raw_affiliation_strings":["Protagonist Therapeutics Pty Ltd, Brisbane, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Protagonist Therapeutics Pty Ltd, Brisbane, Australia","institution_ids":["https://openalex.org/I4387156166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100436684","display_name":"Jie Zhang","orcid":"https://orcid.org/0000-0002-0466-2955","observed_orcids":["https://orcid.org/0000-0002-0466-2955"]},"institutions":[{"id":"https://openalex.org/I4387156166","display_name":"Protagonist Therapeutics (Australia)","ror":"https://ror.org/031xcxv56","country_code":"AU","type":"company","lineage":["https://openalex.org/I4387156166"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Jie Zhang","raw_affiliation_strings":["Protagonist Therapeutics Pty Ltd, Brisbane, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Protagonist Therapeutics Pty Ltd, Brisbane, Australia","institution_ids":["https://openalex.org/I4387156166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108799640","display_name":"Brian T. Frederick","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091875","display_name":"Protagonist Therapeutics (United States)","ror":"https://ror.org/00bp7kt89","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091875"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brian Frederick","raw_affiliation_strings":["Protagonist Therapeutics, Newark, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Protagonist Therapeutics, Newark, CA","institution_ids":["https://openalex.org/I4210091875"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030292318","display_name":"Tran T. Tran","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387156166","display_name":"Protagonist Therapeutics (Australia)","ror":"https://ror.org/031xcxv56","country_code":"AU","type":"company","lineage":["https://openalex.org/I4387156166"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Tran T Tran","raw_affiliation_strings":["Protagonist Therapeutics Pty Ltd, Brisbane, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Protagonist Therapeutics Pty Ltd, Brisbane, Australia","institution_ids":["https://openalex.org/I4387156166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014185322","display_name":"Ashok Bhandari","orcid":"https://orcid.org/0000-0002-3706-0272","observed_orcids":["https://orcid.org/0000-0002-3706-0272"]},"institutions":[{"id":"https://openalex.org/I4210091875","display_name":"Protagonist Therapeutics (United States)","ror":"https://ror.org/00bp7kt89","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091875"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ashok Bhandari","raw_affiliation_strings":["Protagonist Therapeutics, Newark, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Protagonist Therapeutics, Newark, CA","institution_ids":["https://openalex.org/I4210091875"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007295079","display_name":"Jayanthi Vengalam","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091875","display_name":"Protagonist Therapeutics (United States)","ror":"https://ror.org/00bp7kt89","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091875"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jayanthi Vengalam","raw_affiliation_strings":["Protagonist Therapeutics, Newark, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Protagonist Therapeutics, Newark, CA","institution_ids":["https://openalex.org/I4210091875"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089120747","display_name":"Jaimee McMahon","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387156166","display_name":"Protagonist Therapeutics (Australia)","ror":"https://ror.org/031xcxv56","country_code":"AU","type":"company","lineage":["https://openalex.org/I4387156166"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Jaimee McMahon","raw_affiliation_strings":["Protagonist Therapeutics Pty Ltd, Brisbane, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Protagonist Therapeutics Pty Ltd, Brisbane, Australia","institution_ids":["https://openalex.org/I4387156166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006229686","display_name":"Keith Huie","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091875","display_name":"Protagonist Therapeutics (United States)","ror":"https://ror.org/00bp7kt89","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091875"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Keith Huie","raw_affiliation_strings":["Protagonist Therapeutics, Newark, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Protagonist Therapeutics, Newark, CA","institution_ids":["https://openalex.org/I4210091875"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042149364","display_name":"Grace A. Ledet","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091875","display_name":"Protagonist Therapeutics (United States)","ror":"https://ror.org/00bp7kt89","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091875"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Grace A Ledet","raw_affiliation_strings":["Protagonist Therapeutics, Newark, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Protagonist Therapeutics, Newark, CA","institution_ids":["https://openalex.org/I4210091875"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100449628","display_name":"Li Zhao","orcid":"https://orcid.org/0000-0003-1576-8787","observed_orcids":["https://orcid.org/0000-0003-1576-8787"]},"institutions":[{"id":"https://openalex.org/I4210091875","display_name":"Protagonist Therapeutics (United States)","ror":"https://ror.org/00bp7kt89","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091875"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Li Zhao","raw_affiliation_strings":["Protagonist Therapeutics, Newark, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Protagonist Therapeutics, Newark, CA","institution_ids":["https://openalex.org/I4210091875"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051462820","display_name":"James Tovera","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091875","display_name":"Protagonist Therapeutics (United States)","ror":"https://ror.org/00bp7kt89","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091875"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"James Tovera","raw_affiliation_strings":["Protagonist Therapeutics, Newark, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Protagonist Therapeutics, Newark, CA","institution_ids":["https://openalex.org/I4210091875"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031804507","display_name":"Larry Lee","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091875","display_name":"Protagonist Therapeutics (United States)","ror":"https://ror.org/00bp7kt89","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091875"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Larry Lee","raw_affiliation_strings":["Protagonist Therapeutics, Newark, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Protagonist Therapeutics, Newark, CA","institution_ids":["https://openalex.org/I4210091875"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101931350","display_name":"Bo Yang","orcid":"https://orcid.org/0000-0002-1572-9764","observed_orcids":["https://orcid.org/0000-0002-1572-9764","https://orcid.org/0009-0002-2156-1918","https://orcid.org/0009-0005-6113-3848"]},"institutions":[{"id":"https://openalex.org/I4210091875","display_name":"Protagonist Therapeutics (United States)","ror":"https://ror.org/00bp7kt89","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091875"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bo Yang","raw_affiliation_strings":["Protagonist Therapeutics, Newark, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Protagonist Therapeutics, Newark, CA","institution_ids":["https://openalex.org/I4210091875"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021719197","display_name":"Celino Dion","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091875","display_name":"Protagonist Therapeutics (United States)","ror":"https://ror.org/00bp7kt89","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091875"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Celino Dion","raw_affiliation_strings":["Protagonist Therapeutics, Newark, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Protagonist Therapeutics, Newark, CA","institution_ids":["https://openalex.org/I4210091875"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044725606","display_name":"Lucy Yuan","orcid":"https://orcid.org/0000-0002-3417-1225","observed_orcids":["https://orcid.org/0000-0002-3417-1225"]},"institutions":[{"id":"https://openalex.org/I4210091875","display_name":"Protagonist Therapeutics (United States)","ror":"https://ror.org/00bp7kt89","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091875"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lucy Yuan","raw_affiliation_strings":["Protagonist Therapeutics, Newark, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Protagonist Therapeutics, Newark, CA","institution_ids":["https://openalex.org/I4210091875"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082221128","display_name":"Genet Zemede","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091875","display_name":"Protagonist Therapeutics (United States)","ror":"https://ror.org/00bp7kt89","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091875"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Genet Zemede","raw_affiliation_strings":["Protagonist Therapeutics, Newark, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Protagonist Therapeutics, Newark, CA","institution_ids":["https://openalex.org/I4210091875"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Michelle Nguyen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091875","display_name":"Protagonist Therapeutics (United States)","ror":"https://ror.org/00bp7kt89","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091875"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michelle Nguyen","raw_affiliation_strings":["Protagonist Therapeutics, Newark, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Protagonist Therapeutics, Newark, CA","institution_ids":["https://openalex.org/I4210091875"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014443913","display_name":"Mohammad R. Masjedizadeh","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091875","display_name":"Protagonist Therapeutics (United States)","ror":"https://ror.org/00bp7kt89","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091875"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mohammad Masjedizadeh","raw_affiliation_strings":["Protagonist Therapeutics, Newark, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Protagonist Therapeutics, Newark, CA","institution_ids":["https://openalex.org/I4210091875"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068964043","display_name":"Xiaoli Cheng","orcid":"https://orcid.org/0000-0003-1451-7003","observed_orcids":["https://orcid.org/0000-0003-1451-7003"]},"institutions":[{"id":"https://openalex.org/I4210091875","display_name":"Protagonist Therapeutics (United States)","ror":"https://ror.org/00bp7kt89","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091875"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Xiaoli Cheng","raw_affiliation_strings":["Protagonist Therapeutics, Newark, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Protagonist Therapeutics, Newark, CA","institution_ids":["https://openalex.org/I4210091875"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112250688","display_name":"Larry C. Mattheakis","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091875","display_name":"Protagonist Therapeutics (United States)","ror":"https://ror.org/00bp7kt89","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091875"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Larry Mattheakis","raw_affiliation_strings":["Protagonist Therapeutics, Newark, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Protagonist Therapeutics, Newark, CA","institution_ids":["https://openalex.org/I4210091875"]}]},{"author_position":"middle","author":{"id":null,"display_name":"David Liu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091875","display_name":"Protagonist Therapeutics (United States)","ror":"https://ror.org/00bp7kt89","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091875"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Liu","raw_affiliation_strings":["Protagonist Therapeutics, Newark, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Protagonist Therapeutics, Newark, CA","institution_ids":["https://openalex.org/I4210091875"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5059952901","display_name":"Mark L. Smythe","orcid":"https://orcid.org/0000-0001-7840-1021","observed_orcids":["https://orcid.org/0000-0001-7840-1021"]},"institutions":[{"id":"https://openalex.org/I4387156166","display_name":"Protagonist Therapeutics (Australia)","ror":"https://ror.org/031xcxv56","country_code":"AU","type":"company","lineage":["https://openalex.org/I4387156166"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Mark L Smythe","raw_affiliation_strings":["Protagonist Therapeutics Pty Ltd, Brisbane, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Protagonist Therapeutics Pty Ltd, Brisbane, Australia","institution_ids":["https://openalex.org/I4387156166"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.1579,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":{"value":0.51402251,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":97},"biblio":{"volume":"136","issue":"Supplement 1","first_page":"47","last_page":"48"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10452","display_name":"Iron Metabolism and Disorders","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10452","display_name":"Iron Metabolism and Disorders","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11297","display_name":"Ferroptosis and cancer prognosis","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10911","display_name":"Chemical Synthesis and Analysis","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/oral-bioavailability","display_name":"oral bioavailability","score":0.8090000152587891},{"id":"https://openalex.org/keywords/iron-overload","display_name":"iron overload","score":0.8379999995231628},{"id":"https://openalex.org/keywords/iron-homeostasis","display_name":"iron homeostasis","score":0.8650000095367432},{"id":"https://openalex.org/keywords/hereditary-hemochromatosis","display_name":"hereditary hemochromatosis","score":0.9200000166893005},{"id":"https://openalex.org/keywords/polycythemia-vera","display_name":"polycythemia vera","score":0.9089999794960022},{"id":"https://openalex.org/keywords/ferroportin","display_name":"ferroportin","score":0.9599999785423279},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9229999780654907},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9539999961853027},{"id":"https://openalex.org/keywords/mouse-model","display_name":"mouse model","score":0.5699999928474426}],"concepts":[{"id":"https://openalex.org/C2776768029","wikidata":"https://www.wikidata.org/wiki/Q14882371","display_name":"Hepcidin","level":3,"score":0.8901329636573792},{"id":"https://openalex.org/C2776710925","wikidata":"https://www.wikidata.org/wiki/Q24777245","display_name":"Ferroportin","level":4,"score":0.8685294389724731},{"id":"https://openalex.org/C3018783601","wikidata":"https://www.wikidata.org/wiki/Q3144934","display_name":"Hereditary hemochromatosis","level":3,"score":0.6797365546226501},{"id":"https://openalex.org/C2776590208","wikidata":"https://www.wikidata.org/wiki/Q2025687","display_name":"Hemochromatosis","level":2,"score":0.6519614458084106},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5099214315414429},{"id":"https://openalex.org/C2778248108","wikidata":"https://www.wikidata.org/wiki/Q5445","display_name":"Anemia","level":2,"score":0.45085304975509644},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4302927851676941},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.42953407764434814},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.42594051361083984},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.39075756072998047},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.37881070375442505},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3405954837799072},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.3256474733352661},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.25244075059890747},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2020-141720","doi":"https://doi.org/10.1182/blood-2020-141720","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-141720","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9763000011444092}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7135050539","https://openalex.org/W2979561876","https://openalex.org/W2146444665","https://openalex.org/W3118931011","https://openalex.org/W2220192676","https://openalex.org/W2023209642","https://openalex.org/W2122610070","https://openalex.org/W4411941835","https://openalex.org/W3128049423","https://openalex.org/W3126422978"],"abstract_inverted_index":{"Hepcidin":[0,42,165],"peptidomimetics":[1],"that":[2,19,30,96],"are":[3,97],"orally":[4,477],"stable":[5,99,478],"and":[6,27,50,109,139,146,166,186,208,211,228,236,239,248,258,284,289,398,479,485,506,549,552],"systemically":[7,104,480],"active":[8,111,481],"will":[9],"mark":[10],"a":[11,129,197,368,379,460,544],"paradigm":[12],"change":[13],"in":[14,28,58,71,75,100,112,117,125,128,150,178,196,202,234,245,251,273,276,297,301,363,367,403,426,451,455,467,489,494,519,589,623,633,649,665,675,685,695,705,715],"management":[15],"of":[16,55,86,143,191,199,215,242,265,295,310,351,377,382,392,400,407,416,500,511,526,546],"blood":[17],"disorders":[18],"exhibit":[20],"aberrant":[21,408],"iron":[22,37,45,56,74,115,299,319,365,402,409,421,453,462,492,501,517,528,538],"homeostasis":[23,38,57,410,539],"(e.g.":[24,39],"hereditary":[25,133,187,520],"hemochromatosis)":[26],"conditions":[29],"can":[31,513],"be":[32,69],"influenced":[33],"by":[34,390,412,434],"modulating":[35],"stressed":[36,537],"polycythemia":[40,184,547],"vera).":[41],"modulates":[43],"the":[44,52,59,101,192,206,262,268,348,413,417,468,504,507,523],"exporter":[46],"membrane":[47],"protein":[48],"ferroportin":[49,153],"is":[51,172,388],"master":[53],"regulator":[54,381],"body.":[60],"Orally":[61],"bioavailable":[62],"\"Minihepcidins\"":[63],"have":[64,141,475],"been":[65],"previously":[66],"shown":[67],"to":[68,279,326,443,535],"efficacious":[70],"lowering":[72,364,510],"serum":[73,114,298,318,349],"mice":[76,278],"when":[77,106],"dosed":[78],"peroral":[79],"(PO)":[80],"(Preza":[81],"GC":[82],"et.":[83],"al.,":[84],"Journal":[85],"Clinical":[87],"Investigation":[88],"2011).":[89],"Here":[90],"we":[91,121],"describe":[92],"hepcidin":[93,175,383,482,533],"mimetic":[94,176,483,534],"peptides":[95,193,225,269,341,484],"metabolically":[98],"gastrointestinal":[102],"tract,":[103],"absorbed":[105],"delivered":[107],"orally,":[108],"pharmacodynamically":[110],"reducing":[113],"parameters":[116,127],"pre-clinical":[118],"models.":[119],"Further,":[120],"also":[122],"demonstrate":[123],"improvement":[124],"disease":[126],"mouse":[130,246,369,386],"model":[131,370,387],"for":[132,164,169,183,224,272,339,360,371,437],"hemochromatosis.":[134,521],"The":[135,449,497],"oral":[136,487,532],"peptides,":[137],"PN20076":[138,227,230,288,311,352,356,430],"PN20089,":[140],"EC50":[142,160],"16.5":[144],"nM":[145,148,163,168],"1.39":[147],"respectively":[149],"cell":[151],"based":[152],"internalization":[154],"assay":[155],"(Table":[156],"1).":[157,343],"In":[158],"comparison":[159],"was":[161,194,321,353,357,423,464],"67.8":[162],"6.12":[167],"PTG-300.":[170],"(PTG-300":[171],"an":[173,531],"injectable":[174],"currently":[177],"Phase":[179],"2":[180],"clinical":[181],"studies":[182],"vera":[185,548],"hemochromatosis.)":[188],"Oral":[189],"stability":[190,233,257],"evaluated":[195,359],"panel":[198],"assays,":[200,267],"including":[201],"vitro":[203],"matrices":[204,214],"simulating":[205],"gastric":[207,235],"intestinal":[209,237],"conditions,":[210,238],"ex":[212],"vivo":[213,274],"serum/plasma":[216],"from":[217,261,323,503],"different":[218],"species.":[219],"Table":[220],"1":[221],"shows":[222],"data":[223,260],"PN20018,":[226],"PN20089.":[229],"demonstrated":[231,486],"extended":[232],"degradation":[240],"half-life":[241],">24":[243],"hr":[244,250,316,336,346],"plasma":[247],"14.8":[249],"rat":[252],"serum.":[253],"Based":[254],"on":[255],"their":[256,281],"potency":[259],"above":[263],"battery":[264],"screening":[266],"were":[270],"selected":[271],"evaluation":[275],"healthy":[277],"characterize":[280],"pharmacodynamic":[282],"(PD)":[283],"pharmacokinetic":[285],"(PK)":[286],"properties.":[287],"PN20089":[290,313],"showed":[291],"equivalent":[292],"PD":[293],"response":[294],"reduction":[296,450,499,525],"concentration":[300,320,350,454],"wild":[302],"type":[303],"mice.":[304,496],"After":[305],"two":[306,439],"successive":[307],"PO":[308,435],"doses":[309],"or":[312],"approximately":[314],"24":[315],"apart,":[317],"reduced":[322],"~30":[324],"\u00b5M":[325,328],"~10":[327],"(group":[329],"averages),":[330],"i.e.":[331],"~66%":[332],"reduction,":[333],"at":[334],"4.5":[335,345],"post-second":[337],"dose":[338],"both":[340],"(Fig.":[342,447],"At":[344],"post-dose,":[347],"~262":[354],"nM.":[355],"further":[358],"its":[361],"effect":[362],"overload":[366,493],"hemochromatosis":[372,495],"(HFE2-/-":[373],"with":[374,429,472,530],"homozygous":[375],"deletion":[376],"hemojuvelin,":[378],"positive":[380],"expression).":[384],"This":[385],"marked":[389],"hyper-absorption":[391],"dietary":[393],"iron,":[394],"higher":[395],"transferrin":[396],"saturation":[397],"deposition":[399],"excessive":[401,542],"liver,":[404],"all":[405],"manifestations":[406],"caused":[411],"genetic":[414],"disruptions":[415],"hepcidin-iron":[418],"pathway.":[419],"Liver":[420],"accumulation":[422],"significantly":[424],"prevented":[425],"groups":[427],"treated":[428,445,471],"once":[431],"daily":[432],"(QD)":[433],"administration":[436],"over":[438],"weeks,":[440],"as":[441],"compared":[442],"vehicle":[444],"controls":[446],"2).":[448],"non-heme":[452],"liver":[456,491],"homogenates":[457],"(measured":[458],"using":[459],"colorimetric":[461],"assay)":[463],"statistically":[465],"significant":[466],"female":[469],"group":[470],"PN20076.":[473],"We":[474],"described":[476],"activity":[488],"preventing":[490],"effective":[498],"absorption":[502],"diet":[505],"steady":[508],"state":[509],"transferrin-saturation":[512],"potentially":[514],"prevent":[515],"tissue":[516],"toxicity":[518],"Similarly,":[522],"sustained":[524],"systemic":[527],"levels":[529],"control":[536],"should":[540],"reduce":[541],"erythrocytosis,":[543],"hallmark":[545],"other":[550],"congenital":[551],"acquired":[553],"erythropoietic":[554],"disorders.":[555],"Disclosures":[556],"Bourne:":[557],"Protagonist":[558],"Therapeutics:":[559,565,571,577,583,593,599,605,611,617,627,637,643,653,659,669,679,689,699,709,719],"Current":[560,566,572,578,584,586,594,600,606,612,618,620,628,630,638,644,646,654,660,662,670,672,680,682,690,692,700,702,710,712,720],"Employment,":[561,567,573,579,585,595,601,607,613,619,629,639,645,655,661,671,681,691,701,711,721],"Other:":[562,568,574,580,596,602,608,614,640,656,722],"shareholder.":[563,569,575,581,597,603,609,615,641,657,723],"Zhang:Protagonist":[564],"Frederick:Protagonist":[570],"Tran:Protagonist":[576],"Vengalam:Protagonist":[582],"equity":[587,621,631,647,663,673,683,693,703,713],"holder":[588,622,632,648,664,674,684,694,704,714],"private":[590,624,634,650,666,676,686,696,706,716],"company.":[591,625,635,651,667,677,687,697,707,717],"McMahon:Protagonist":[592],"Huie:Protagonist":[598],"Ledet:Protagonist":[604],"Zhao:Protagonist":[610],"Tovera:Protagonist":[616],"Lee:Protagonist":[626],"Yang:Protagonist":[636],"Dion:Protagonist":[642],"Yuan:Protagonist":[652],"Zemede:Protagonist":[658],"Nguyen:Protagonist":[668],"Masjedizadeh:Protagonist":[678],"Cheng:Protagonist":[688],"Mattheakis:Protagonist":[698],"Liu:Protagonist":[708],"Smythe:Protagonist":[718]},"counts_by_year":[{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":1}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2020-11-09T00:00:00"}